Aruni Ghose: Delighted to see our prospective blinded validation trial on the URO17 urinary bladder cancer biomarker published in BMC Urology by Springer Nature Group
Aruni Ghose, Focused Topic Network Member at
”Delighted to see our prospective blinded validation trial on the URO17 urinary bladder cancer biomarker published in BMC Urology by Springer Nature Group.
Designed by KDx Diagnostics Inc., Sholeh Jahanfard, John Cucci – this was a multi-centre study between East and North Hertfordshire NHS Trust and King Hamad University Hospital – Bahrain designed by the pioneering Prof Nikhil Vasdev.
URO17 had an overall sensitivity of 98%, NPV 98%, PPV 67%, specificity 74% in 149 patients, implying effective diagnosis of urothelial tumours (especially upper tract) and recurrence in non-muscle invasive bladder cancer.
It is reliable in the diagnosis and follow up of bladder cancer patients, non-invasive, cost-effective (£110 per test vs £229 to £258 per flexible cystosocopy). As a screening tool, it is a good adjunct to flexible cystoscopy.
Primetime for a Multicentre UK evaluation? Excited for the future in this space. International Colleagues thoughts – Ravindran Kanesvara, Yüksel ÜRÜN, Sara Elena Rebuzzi, Jeremy Teoh, Sumanta Pal, Neeraj Agarwal.
Looking forward to seeing URO17 making noise at the UK Oncology Forum in Brighton June 2024 Sharon Poole, ATHENA MEETINGS AND EVENTS LIMITED+ International Urology Cancer Summit in Portsmouth September 2024?”
Read further.
Source: Aruni Ghose/LinkedIn